You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR NELARABINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Nelarabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed Children's Cancer Group Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003545 ↗ 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed Southwest Oncology Group Phase 2 1998-08-01 Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nelarabine

Condition Name

Condition Name for Nelarabine
Intervention Trials
Leukemia 7
Lymphoblastic Lymphoma 4
Acute Lymphoblastic Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nelarabine
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 20
Leukemia, Lymphoid 19
Leukemia 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nelarabine

Trials by Country

Trials by Country for Nelarabine
Location Trials
United States 177
Germany 12
Canada 12
Australia 8
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nelarabine
Location Trials
Texas 13
California 11
Ohio 8
New York 7
Illinois 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nelarabine

Clinical Trial Phase

Clinical Trial Phase for Nelarabine
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 1
Phase 2 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nelarabine
Clinical Trial Phase Trials
Completed 12
Recruiting 9
Terminated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nelarabine

Sponsor Name

Sponsor Name for Nelarabine
Sponsor Trials
National Cancer Institute (NCI) 13
GlaxoSmithKline 6
M.D. Anderson Cancer Center 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nelarabine
Sponsor Trials
Other 44
Industry 22
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Nelarabine: Clinical Trials, Market Analysis, and Projections

Introduction to Nelarabine

Nelarabine, an antimetabolite prodrug, is a crucial medication in the treatment of acute T-cell lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). It is converted into its active form, arabinosylguanine nucleotide triphosphate, which inhibits DNA synthesis and leads to cell death, making it an effective agent against these cancers[2][4].

Clinical Trials Update

Frontline Treatment Trials

Several ongoing clinical trials are evaluating the efficacy and safety of nelarabine in the frontline treatment of T-ALL. The GRAALL-2014/T trial and the JPLSG T-11/JALSG T-ALL-211-U trial are notable examples.

  • GRAALL-2014/T Trial: This trial compares a modified chemotherapy regimen that includes nelarabine to historical regimens. Patients aged 45-59 received a less intense chemotherapy regimen with a modified hematopoietic stem cell transplant (HSCT). Nelarabine was administered at 1.5 g/m² on days 1, 3, and 5 during consolidation and maintenance. The 3-year overall survival rate was 71% with the modified regimen, compared to 64% without nelarabine, although the trial is still ongoing and final data on nelarabine's impact are pending[1].

  • JPLSG T-11/JALSG T-ALL-211-U Trial: This trial involved 62 patients with a median age of 17 years and used nelarabine at 650 mg/m² for 5 days during intensification and maintenance. The results showed a 3-year event-free survival (EFS) rate of 88.6%, an overall survival (OS) rate of 93.4%, and a cumulative incidence of relapse rate of 5.3%. These outcomes suggest that nelarabine could be a valuable addition to frontline therapy for adults with T-ALL[1].

Relapsed/Refractory T-ALL/LBL Trials

Nelarabine is also being studied in combination regimens for relapsed or refractory (R/R) T-ALL/LBL.

  • Combination Therapy: A retrospective analysis of 44 patients treated with nelarabine alone or in combination with cyclophosphamide and etoposide (NECTAR) showed that combination therapy achieved a complete remission rate of 62%, compared to 40% with monotherapy. This study highlights the potential of nelarabine in combination regimens as a bridge to transplantation for R/R T-ALL/LBL patients[4].

  • Pediatric and Adult Response Rates: In children with first or second relapse of T-ALL/LBL, response rates were 55% and 27%, respectively. In adults, approximately one-third of patients in first or later relapse achieved complete remission. These results support the use of nelarabine in both pediatric and adult populations with R/R T-ALL/LBL[4].

Market Analysis

Current Market Size

The global market for nelarabine was estimated to be worth US$ 134 million in 2023. This market is driven by the drug's efficacy in treating T-ALL and the increasing awareness and diagnosis of this condition[5].

Market Projections

The nelarabine market is forecasted to grow to US$ 146.3 million by 2030, with a compound annual growth rate (CAGR) of 1.1% during the period from 2024 to 2030. This growth is attributed to advancements in the healthcare sector, higher investment in developed regions, and the drug's status as a first-in-class medication for leukemia treatment[5].

Regional Market

The market for nelarabine is expected to be more expansive in developed regions such as North America and Europe, where healthcare investments are higher and awareness about health conditions is greater. However, the demand for nelarabine is global due to the widespread nature of T-ALL and LBL[2].

Competitive Landscape

Key players in the nelarabine market include GlaxoSmithKline and Novartis. The competitive landscape is influenced by the drug's approval status, its inclusion in combination therapies, and ongoing clinical trials that may further establish its efficacy and safety[5].

Pharmacoeconomic Analysis

The incremental cost-effectiveness ratio (ICER) for nelarabine compared to standard of care (SOC) alone has been estimated. A study found that the ICER for nelarabine was $26,362 per quality-adjusted life year (QALY) gained, with the majority of the incremental QALYs driven by an assumed survival benefit. This suggests that nelarabine provides significant value in terms of improved survival outcomes, although the long-term effects are still under observation[3].

Patient and Clinician Perspectives

Patients and clinicians have expressed hope for new treatments that offer improved prognosis, fewer and less severe long-term adverse effects, and better treatment logistics. Direct experience with nelarabine has generally been positive, with respondents noting minimal side effects compared to other ALL treatments. Common side effects include low platelet counts, anemia, and extreme sleepiness, which are generally manageable[3].

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on various business aspects, including the healthcare sector. However, the nelarabine market is expected to maintain an optimistic outlook due to its critical role in treating leukemia. The pandemic has highlighted the importance of effective and reliable treatments, which has supported the continued demand for nelarabine[2].

Key Takeaways

  • Clinical Trials: Ongoing trials such as GRAALL-2014/T and JPLSG T-11/JALSG T-ALL-211-U are evaluating nelarabine's efficacy in frontline T-ALL treatment, showing promising results.
  • Market Growth: The global nelarabine market is projected to grow to US$ 146.3 million by 2030, driven by its efficacy and increasing healthcare investments.
  • Pharmacoeconomic Value: Nelarabine offers significant value in terms of improved survival outcomes, with an ICER of $26,362 per QALY gained.
  • Patient and Clinician Perspectives: Nelarabine is generally well-tolerated with minimal side effects, offering improved treatment logistics and prognosis.
  • COVID-19 Impact: Despite pandemic challenges, the nelarabine market remains optimistic due to its critical role in leukemia treatment.

FAQs

What is nelarabine used for?

Nelarabine is used for the treatment of acute T-cell lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL), particularly in relapsed or refractory cases[4].

What are the key clinical trials evaluating nelarabine?

Key trials include the GRAALL-2014/T trial and the JPLSG T-11/JALSG T-ALL-211-U trial, which are assessing nelarabine's efficacy in frontline T-ALL treatment[1].

What is the projected market size for nelarabine by 2030?

The global market for nelarabine is forecasted to reach US$ 146.3 million by 2030, with a CAGR of 1.1% from 2024 to 2030[5].

What are the common side effects of nelarabine?

Common side effects include low platelet counts, anemia, low red blood cell counts, low white blood cell counts, and extreme sleepiness[3].

How does nelarabine compare to standard of care in terms of cost-effectiveness?

Nelarabine has an ICER of $26,362 per QALY gained compared to standard of care alone, indicating significant value in improved survival outcomes[3].

How has the COVID-19 pandemic affected the nelarabine market?

Despite the pandemic's impact on various business aspects, the nelarabine market is expected to maintain an optimistic outlook due to its critical role in treating leukemia[2].

Sources

  1. Targeted Oncology: "In T-ALL, Early Nelarabine and Daratumumab Trials Offer Promising Safety, Efficacy" - September 7, 2023.
  2. Reports and Data: "Nelarabine Market Size, Growth | Industry Analysis, 2017-2027".
  3. NCBI Bookshelf: "Pharmacoeconomic Review - Nelarabine (Atriance)".
  4. Blood Advances: "Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoma" - March 29, 2023.
  5. Valuates Reports: "Nelarabine - Market, Report Size, Worth, Revenue, Growth, Industry Research".

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.